Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recurrent MTOR Mutations in Renal Cell Carcinoma With Fibromyomatous Stroma: A Report of 2 Tumors.

International journal of surgical pathology - 1 Oct 2024

Palathingal Bava Ejas, Gupta Nilesh, Alruwaii Fatimah I, Nelson Ryan, Al-Obaidy Khaleel I

Abstract excerpt

Renal cell carcinoma with fibromyomatous stroma, recognized as a provisional entity in the current 2022 World Health Organization classification of renal neoplasms, is rare. Recent evidence suggests recurrent alterations in the mTOR pathway, supporting its recognition as a distinct entity. Herein, we report 2 renal cell carcinomas with fibromyomatous stroma with MTOR mutations occurring in 62- and 72-year-old...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Renal Cell

Share to Kidney Neoplasms

Share to Mutation

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 38311893
DOI: 10.1177/10668969241228295

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recurrent MTOR Mutations in Renal Cell Carcinoma With Fibromyomatous Stroma: A Report of 2 Tumors.PMID 38311893Read ↗

Mutated ASXL1 upregulates mTOR expression in renal cell carcinoma with fibromyomatous stroma.Semantic proximity Read ↗

[Clinicopathological features of TSC/mTOR mutation-associated renal cell carcinoma with leiomyomatous stroma: report of nine cases].Semantic proximity Read ↗

Metastatic renal cell carcinoma with fibromyomatous stroma associated with tuberous sclerosis or MTOR, TSC1/TSC2-Mutations: A Series of 4 cases and a review of the literature.Semantic proximity Read ↗

Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic SettingSemantic proximity Read ↗

Review: Mammalian Target of Rapamycin (mTOR) Pathway Is Critical in Developing Most Renal Cell Tumors.Semantic proximity Read ↗

"Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.Semantic proximity Read ↗

Transcriptomic Profiling Identifies a Subset of Renal Tumours with Overlapping Features of Clear Cell Papillary Renal Cell Tumour and Renal Cell Carcinoma with Fibromyomatous StromaSemantic proximity Read ↗

Xanthomatous giant cell renal cell carcinoma: clinicopathologic and molecular characterization of 2 additional cases with biallelic TSC2 mutations.Semantic proximity Read ↗

Comprehensive Analysis of 15 Cases of ELOC-RCC and Identification of Novel Mutation SiteSemantic proximity Read ↗

Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases.Semantic proximity Read ↗

Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney.Semantic proximity Read ↗

Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-upSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.